FDA's AI Guidance: 7-Step Credibility Framework Explained

In January 2025 the U.S. Food and Drug Administration (FDA) issued draft guidance on the use of artificial intelligence (AI) in drug and biological product development, describing a comprehensive 7-step credibility assessment framework (^[2]) (^[3]). The draft guidance recommends that sponsors define the regulatory question the AI model is intended to address and its context of use (COU), assess model risk (based on model influence and decision consequence), develop and execute a credibility assessment plan aligned with that risk, and document the outcomes. At its core, the approach is risk-based – higher-risk AI applications (e.g., those directly affecting patient safety or product quality) may warrant more rigorous credibility assessments, documentation, and lifecycle maintenance than lower-risk uses (^[4]) (^[5]).

Our report provides an in-depth analysis of this framework. We trace the historical context of AI in drug development and regulatory engagement, then unpack each of the seven steps with detailed explanation and examples. We draw on FDA source documents and expert analyses to illustrate how sponsors should define the question of interest, articulate the COU, quantify model risk, plan and carry out validation, and decide if the model’s performance is adequate. Crucial themes include the need for fit-for-use, high-quality data, thorough performance metrics (e.g. accuracy, bias checks, uncertainty quantification), and documentation of any deviations or life-cycle changes (^[5]) (^[6]).

We also examine multiple perspectives: how the industry is preparing (including case examples from bioprocess simulation and pharmaceuticals manufacturing), concerns about intellectual property versus transparency (^[7]), and parallels with international guidelines (e.g. EMA’s AI reflection paper) and academic recommendations for AI model validation (^[8]) (^[9]). For instance, Ark Biotech presents an illustrative bioreactor-simulation scenario for antibody production in which a hybrid AI model is used to explore process parameters; it does not report an observed outcome replacing physical trials (^[10]). Stakeholders from law firms to healthcare system CIOs emphasize early FDA engagement and robust risk management as best practices (^[11]) (^[12]).

Finally, we discuss broader implications. The guidance’s emphasis on transparency and documentation spurs innovation (e.g. explainable models, automated reporting tools) (^[6]) and may influence intellectual property strategies. Future directions include finalizing the guidance after public comments, global harmonization (the FDA is already working with other regulators), and ongoing FDA support initiatives. In sum, the FDA’s framework outlines how to build trustworthy AI in drug development, requiring a clear rationale, strong evidence, and continuous oversight to ensure patient safety and product quality while fostering innovation (^[13]) (^[14]).

Artificial intelligence is increasingly transforming biomedical research and drug development. Machine learning models and advanced algorithms are now used at every stage – from in silico compound screening and trial design to manufacturing process optimization and post-market surveillance (^[15]) (^[16]). Since 2016, the FDA has received more than 500 drug and biological-product submissions with AI components (^[16]) (^[13]) and running workshops (e.g. with Duke’s CTTI in 2024 (^[17])) and public discussions on AI. Yet regulators and sponsors have struggled with how to ensure these models are reliable and safe when making high-stakes decisions. Recognizing both the promise and perils of AI, the FDA in early 2025 released its first guidance specifically on AI in drug and biologic development (^[2]) (^[18]).

The FDA’s draft guidance – titled Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (FDA-2024-D-4689) – is part of this ongoing effort. It complements earlier AI-related guidance (e.g. for AI-enabled medical devices in 2023) by focusing on drugs/biologics. The document provides recommendations to sponsors on using AI to produce data or information that will support regulatory decisions about safety, effectiveness or quality (^[19]). In doing so, it introduces a risk-based credibility assessment framework for AI models, providing nonbinding recommendations for establishing and evaluating an AI model’s credibility for a particular context of use (^[20]) (^[3]).

Key motivations for this guidance include: (1) Regulatory experience – since 2016 the FDA has seen a sharp rise in AI applications in submissions, now totaling hundreds of cases (^[13]) (^[16]); (2) Stakeholder input – the guidance builds on an FDA-led workshop (Duke Margolis, 2022) and over 800 public comments on prior AI discussion papers in 2023 (^[21]) (^[12]); and (3) Public health – given the impact AI could have on patient safety and drug quality, FDA needs clear policies that balance innovation with its statutory safety standards (^[22]). As Commissioner Califf explained, “With the appropriate safeguards in place, AI has transformative potential to advance medical product development”—but those safeguards must include robust technical and regulatory checklists (^[22]).

Conceptual framing. In this guidance, FDA defines an AI system broadly as any “machine-based system that can…make predictions, recommendations, or decisions influencing real or virtual environments” (^[23]). The focus is on maps of reality – data-driven models that produce outputs (e.g. risk scores, image classifications) intended to influence a regulatory question. Importantly, the guidance repeatedly emphasizes context of use (COU), a term FDA uses to describe “how and in what context” a model addresses a specific question (^[24]) (^[20]). COU includes the model’s scope, its inputs/outputs, and its role relative to other evidence. It also defines credibility in a regulatory sense: “trust, established through the collection of credibility evidence, in the performance of an AI model for a particular COU” (^[20]). Thus, an AI model is not inherently acceptable or not – its credibility depends on whether there is trustworthy evidence that it works for the specified decision task.

The guidance expressly excludes certain AI uses: it does not apply to AI for early drug discovery (e.g. target ID or lead optimization) or purely internal business tasks. Instead, it applies to situations where an AI-generated output will be used in a submission or quality system that directly affects patient safety, drug efficacy, or manufacturing/compliance decisions (^[24]) (^[25]). Examples include AI-driven trial designs, predictive models for patient outcomes, R&D tools for digital biomarkers, pharmacovigilance analytics, and manufacturing process controls (^[26]) (^[27]). But if AI is used only to speed engineering of a molecule before safety/efficacy are assessed, it lies outside the guidance’s scope (^[25]).

In summary, the FDA guidance aims to advance trustworthy AI in drug development by offering sponsors a risk-based framework to plan and document credibility evidence for models in context. It essentially offers a roadmap – the seven steps – for building a regulatory submission with credible AI. The rest of this report explains each aspect in depth, showing how the framework works and what it means for the future of drug development.

The heart of the FDA’s draft guidance is a seven-step, risk-based framework to evaluate the credibility of AI models for a defined COU (^[3]) (^[28]). Below we explain each step, synthesizing regulatory text, expert commentary, and concrete examples. (A summary table of the steps is provided at the end of this section.)

Step 1: Define the Question of Interest

Before building or validating an AI model, sponsors should clearly articulate the question of interest it is intended to address (^[24]) (^[29]). This step sets the stage for everything that follows. It involves specifying the precise decision or outcome the AI’s output will influence, aligned with FDA-defined objectives such as safety, efficacy, or quality.

For example, in a clinical trial setting the question might be, “Which trial participants are sufficiently low-risk that they need only outpatient monitoring after receiving Drug X in study Y?” (^[30]). That question implicates patient safety (are we at risk of missing adverse events?) and guides the model’s design. In manufacturing, a question could be, “Do the vials produced in batch Z of Drug Y meet our fill-volume specifications?” (^[31]). This concerns product quality and compliance.

Defining the question of interest forces sponsors to tie their AI use-case to a concrete decision. As Foley LLP notes, examples could include trial inclusion criteria, patient risk stratification, or adjudicating clinical endpoints (^[32]). At this stage, sponsors should also identify contextual evidence or background data supporting the question – for instance, historical trial results or prior process performance. Crucially, the question determines the intended use: whether the AI output will “inform” a decision (with human review) or actually make the decision autonomously. As the FDA highlights, models making final determinations without human oversight generally carry higher risk and thus demand stronger evidence (^[5]).

In summary, Step 1 ensures that the AI effort is problem-driven. By articulating the question of interest, sponsors define the model’s purpose and boundaries. All subsequent planning – from defining inputs and performance criteria to assessing risk – centers on this question. Without a specific question, the framework cannot be applied.

Step 2: Define the Context of Use (COU)

Having identified the question, Step 2 requires sponsors to describe how the AI model will be used to address it, i.e. its context of use (^[33]) (^[34]). COU includes the operational details and scope surrounding the model: what data it ingests, what output it produces, and how that output will be integrated into decision-making. It also specifies any boundaries (e.g. patient populations, manufacturing conditions) in which the model is expected to work.

Precisely defining the COU is critical because it informs the level of stringency needed in validation. For instance, if the COU specifies that the model’s output will only be one input among many in a decision process (with a human ultimately accountable), the risk is lower than if the model’s result will directly determine an outcome. As one analyst notes, the COU description should spell out whether other information (e.g. lab tests, human review) will complement the AI output, or if the AI is the sole decision-maker (^[35]) (^[36]).

Concrete examples illustrate COU definitions. In a clinical scenario, the COU might be: “The AI model will assign participants to low- or high-risk groups for adverse events based on baseline data (age, labs, genomics), thereby informing monitoring intensity; human clinicians will then apply additional judgment (^[37]).” In a manufacturing context, the COU could be: “Analyze real-time process sensor data to detect deviations in product quality attributes (e.g. fill level); any out-of-spec predictions will be reviewed by quality staff before any corrective action (^[38]).”

In this step, sponsors can outline data considerations for the COU. FDA recommends identifying training, testing, and validation data that are “fit for use” – i.e. relevant and reliable for the intended purpose (^[20]) (^[39]). Data quality criteria (completeness, consistency, etc.) and lifecycle data flows should be detailed. The plan should cover whether real-world data, historical trial data, or prospective data will be used, and how data pivotals like missingness or noise will be handled. The FDA emphasizes that clear data validation processes are needed, especially when using diverse data (such as RWD) (^[40]).

Completing Step 2 yields a comprehensive COU statement that defines the embedded role of AI. This includes: input types, output interpretation, integration with other evidence, operational procedures, environmental constraints, and user interactions. This clarity is the foundation for risk analysis: once the COU is set, sponsors can judge what could go wrong when the model is used as intended.

Step 3: Assess Model Risk

Step 3 applies a risk assessment to the AI model within its COU (^[41]) (^[5]). FDA instructs sponsors to evaluate two core vectors of risk:

• Model Influence – how strongly will the AI output influence the decision or process? Is it one factor among many, or does it solely determine a critical outcome? An AI that operates as a “black box” with full authority is highly influential (and thus higher risk) because its errors directly propagate to decisions (^[5]). By contrast, a model whose output is only advisory or is double-checked by humans has lower influence.

• Decision Consequence – what is the potential harm if the AI output is wrong? This measures severity of an incorrect decision in the given application. For a clinical model predicting adverse events, incorrect stratification could endanger patient safety (high consequence). In manufacturing, an erroneous prediction about a non-critical parameter might have lower consequence (though some failures could still affect product quality) (^[5]).

Combining these factors yields a model risk classification (e.g. Low, Medium, High). As DLA Piper explains, sponsors should consider both the severity of potential errors and the probability of occurrence, possibly using tools like risk matrices or Failure Modes and Effects Analysis (FMEA) (^[42]) (^[41]). For example, a scenario with high influence & high consequence (AI makes an unverified decision on patient monitoring, where an error could be life-threatening) is categorized as high-risk (^[43]) (^[5]). By contrast, low influence & low consequence scenarios (AI assists manufacturing QC but humans ultimately verify) are low-risk. Intermediate combinations yield medium risk.

Assessing risk also involves considering non-clinical threats. Sponsors should evaluate data integrity (training/test splits, label quality), bias (e.g. non-representative samples), adversarial vulnerabilities (e.g. input manipulation), and cybersecurity risks (^[44]). For instance, bias detection should be an integral part of risk analysis, with plans for fairness evaluation across subgroups. Algorithms like Bayesian models, which inherently estimate uncertainty, can inform the risk profile by quantifying confidence (^[45]) (^[46]).

Quantifying model risk has two uses. First, it informs the depth of subsequent credibility activities: higher-risk models require more evidence. The guidance explicitly ties risk to the stringency of validation and documentation (^[7]) (^[41]). Second, it highlights where risk mitigation may be needed (e.g. adding human review, reducing model reliance). In fact, Step 7 (below) eventually checks adequacy of the risk assessment and whether mitigations or evidence supplements are required.

Step 4: Develop a Credibility Assessment Plan

With risk classified, Step 4 directs sponsors to plan how they will demonstrate the model’s credibility for the COU (^[47]) (^[48]). This plan is essentially a project blueprint for all validation and verification activities. It should be tailored to the inferred risk level: the higher the risk, the more comprehensive and rigorous the plan.

FDA recommends that the plan describe the AI model and its development lifecycle, including the model description, data, training or tuning procedures, and proposed evaluation methods. For example, sponsors should specify which data sets will be used for model development vs testing, how data quality will be assessed, and what metrics or acceptance criteria will be used to judge performance (^[47]) (^[48]). Performance metrics might include accuracy, sensitivity/specificity, predictive values, calibration statistics, and uncertainty measures; appropriate choices depend on the task (e.g. a binary safety prediction model vs a continuous process control output). The plan should also describe any strategies for oversampling, cross-validation, or external validation to ensure generalizability.

The draft guidance lists key plan components explicitly: description of the model and data, description of training/tuning data, description of test data, description of model evaluation process, etc (^[47]). Sponsors should address potential sources of error or bias in each component (for example, noting any limitations in training data representativeness and how those will be mitigated). Crucially, life-cycle planning should be included: if the model will learn or drift over time, the plan should outline how continuous monitoring and revalidation will occur (^[36]) (^[49]).

Developing the plan is often iterative; sponsors are encouraged to engage FDA at this stage to align expectations. By planning before full implementation, sponsors can adjust their approach (e.g. gather more data, add controls) if the proposed activities seem insufficient. For high-risk models especially, the plan might call for pre-specified success criteria (e.g., thresholds for false-positive/negative rates) and independent review points.

Step 5: Execute the Credibility Plan

Step 5 is execution: sponsors carry out the planned validation and testing activities (^[50]). In practical terms, this means training the model on the development data, rigorously testing it on hold-out or external datasets, tuning parameters, and conducting any additional analyses such as sensitivity or stress testing. All procedures outlined in the plan must be documented and reproducible.

Typical activities include: model performance evaluation (applying the model to new data and computing agreed-upon metrics), error analysis (examining cases of misclassification or large residuals), and robustness checks (for example, testing stability under varied input conditions or simulated noise). A crucial sub-step is verifying that the evaluation data are truly independent of training data to prevent leakage. If the plan included comparisons to benchmark models or baselines, these should be executed. For dynamic models, execution may also involve prospective validation (monitoring performance on live data as the model is deployed).

During execution, any unexpected results or deviations from the plan should be noted. For instance, if performance is far worse than anticipated, sponsors may pause and investigate data issues or model overfitting. In a well-documented process, all raw results, code, and versioning should be archived for transparency. This data analysis is evidence-based: the plan should have established what counts as a success. Did the model meet the pre-specified acceptance criteria? Did uncertainty bounds overlap tolerances? These questions are answered here.

Step 6: Document Results and Deviations

Step 6 requires compiling a credibility assessment report that details the outcomes of Step 5 (^[51]). The report should be clear, structured, and comprehensive. It must describe the model’s objectives and COU (reiterating Steps 1–2), summarize the validation activities performed, present the performance results (often with tables or plots of metrics), and explicitly note any deviations from the original plan.

Documentation is a fundamental trust-building activity. The report is intended to provide regulators (and internal stakeholders) with evidence that the model meets expectations. As the guidance states, it should describe the results of all credibility activities and explain any changes in methods or unexpected behaviors (^[51]). For example, if a certain subpopulation was underrepresented in the test data, the report should highlight that shortcoming and its implications. If a hyperparameter was adjusted outside the initial range, that change should be logged.

The guidance leaves “whether, when, and where” to submit this report somewhat flexible – it can be part of a regulatory submission, a meeting package, or simply kept on file ready for inspection (^[51]). Nonetheless, sponsors must plan as if the FDA might request it. An organized, readable report might include sections or appendices for code listings, data schemas, and QA checks. The underlying principle is transparency: the more fully one documents, the easier it is for reviewers to assess credibility.

Step 7: Determine Model Adequacy for the COU

The final step is evaluative: Is the AI model adequately credible for its intended use? The sponsor reviews the total evidence and decides whether the model’s performance and risk mitigation meet the standards for that COU. If yes, the model can proceed as proposed. If not, the guidance explicitly outlines five possible follow-up actions (^[52]) (^[53]):

1. Reduce model influence with supplementary evidence. For example, combine the AI output with additional clinical or manufacturing data so that decisions do not rely solely on the model (effectively lowering model influence).

2. Increase validation rigor or data. This means collecting more data or performing deeper tests. For instance, incorporating more training samples or conducting additional external validation to boost confidence in performance.

3. Add risk-mitigating controls. Introduce procedural safeguards (e.g. human review checkpoints, alarms) that reduce the consequences of a potential model error.

4. Modify the modeling approach. If the existing model family isn’t adequate, try a different algorithm, feature set, or approach altogether.

5. Re-scope or reject the model. It may be necessary to narrow the COU, postpone its use, or abandon the model if it cannot be rendered credible.

These options illustrate the iterative nature of credibility assessment. If a model fails to meet acceptance criteria, sponsors do not simply “give up”; they should consider adjustments. For example, if a predictive model for dosing errors proves insufficient on its own, adding an independent laboratory measurement check (supplementary evidence) could down-classify it to a lower influence scenario (^[52]). Conversely, if a high-risk model passes all tests with wide margins, sponsors should still plan life-cycle maintenance.

Life-cycle maintenance. The guidance discusses the importance of maintaining credibility when AI models may change over time (data drift, retraining, etc.) and recommends considering a maintenance plan where appropriate. This goes slightly beyond the seven steps as written, but it is implied here. If the model is deployed, the sponsor should have in place monitoring schedules, re-validation triggers, and version control procedures (^[48]) (^[49]). For instance, a machine learning model used in ongoing pharmacovigilance should have processes to detect if its performance degrades on new safety reports. The credibility plan or report should briefly outline these maintenance actions (though some details might remain as internal SOPs).

By the end of Step 7, the sponsor has addressed the key question: Is this AI model sufficiently credible to support the regulatory decision in question? If not, the draft guidance describes potential follow-up actions. The framework may help sponsors gather and document credibility evidence for a particular context of use; it does not itself establish a mandatory condition for submitting or relying on a model’s results.

The following table summarizes the FDA’s seven-step framework and key activities at each step:

Each step builds on the last, forming a structured workflow. Together, these steps ensure that by the time an AI model is submitted as part of a drug or biologics application, there is transparent evidence that it is trustworthy for its intended purpose. The framework implicitly mirrors traditional risk management: sponsors must define specifications (Steps 1-2), analyze potential failures (Step 3), test and verify (Steps 4-6), and respond to gaps (Step 7) – all in documentation coincident with Good Practices. Throughout, FDA guidance stresses human oversight and interpretability: even if an AI model is complex, outputs must be validated and understandable enough to “foster trust in the credibility of AI model outputs” (^[56]).

Beyond the stepwise process above, fully establishing AI credibility involves deep attention to data quality, validation methodology, and performance metrics. We discuss these cross-cutting themes here, drawing on regulatory guidance and scholarly literature.

Data Quality and “Fit-for-Use”

High-quality data are the lifeblood of credible AI models. The FDA framework repeatedly emphasizes using data that are fit for use – meaning relevant, reliable, and representative for the COU (^[16]) (^[5]). In practice, sponsors should audit their data for completeness, accuracy, and consistency. Outliers and missing values must be handled systematically, and data provenance should be traceable. The NEJM workshop report stresses this: “Fit-for-use data exist across the drug development ecosystem…but often remain siloed… Importantly, the application of fit-for-use data is not absolute…the data quality should be assessed relative to the specific purpose” (^[39]).

Sponsors may need to integrate multiple sources: clinical trial results, laboratory assays, real-world data (RWD) from registries or claims, and manufacturing records. Each source has its own quirks. For example, sensor data from a bioreactor can have time lags or variability that must be characterized. The FDA advises specifying data management procedures in the plan, including how data will be harmonized, cleaned, and stored. A lack of data (common in rare diseases) is a challenge; strategies such as federated learning or synthetic data may be relevant, but require careful validation (^[57]).

From the literature, we know that sample size and representativeness are critical. Guidelines recommend that “the amount of collected data is sufficiently large for the intended purpose” and ideally pre-specified (^[58]). In fact, formal sample size calculations (e.g. requiring a minimum number of events per outcome) may be needed to ensure statistical confidence. Where existing data are limited, sponsors should consider techniques like learning curves or conservative effect-size estimates (^[58]). If data are biased (e.g. unbalanced patient populations), plans should include mitigation (resampling, equalization) and monitoring for bias impacts (^[59]) (^[60]).

Overall, data evidence for credibility includes a clear description of data sources, data quality metrics (e.g. error rates, missingness proportions), and justification of data appropriateness. Demonstrating that training and test data align with the deployment context is key. Many guidance reviewers will scrutinize whether the AI encountered “surprise” scenarios. Thus, comprehensive data analysis – from exploratory statistics to documentation of data lineage – is an indispensable part of credibility evidence (Steps 4–6).

Model Validation and Performance Metrics

Once data are established, rigorous validation activities are essential. The guidance does not prescribe specific algorithms, but it expects that whichever modeling techniques are used, they are thoroughly tested. Standard metrics (e.g. accuracy, sensitivity, specificity, AUROC) are commonly reported (^[8]). In internal data analysis, metrics like positive predictive value or F1-score may also be valuable, depending on the regulatory question. For regression or continuous outputs, error measures (MSE, RMSE) and visualizations (e.g. calibration plots) are useful.

Performance metrics should align with the consequences identified in the risk assessment. For high-consequence tasks (like patient monitoring), emphasis may be on minimizing false negatives (sensitivity) and quantifying uncertainty bounds. For manufacturing quality control, metrics might include defect detection rates and false alarm rates. The planned acceptance criteria (Step 4) should specify target values or ranges for these metrics, preferably benchmarked against current standards or alternative methods.

Because AI models can overfit, external validation is particularly important. This could involve, for example, holding out an entire clinical trial for testing, or using independent laboratory data for validation. The guidance implicitly encourages all forms of validation (cross-validation, prospective trials, retrospective hold-out data, etc.) to build confidence.

Stability testing is also pertinent. For instance, sensitivity analyses (varying input distributions, adding noise, or simulating worst-case scenarios) can reveal model robustness. One academic review found that while performance monitoring strategies are increasingly discussed, practical guidelines are scarce (^[61]). This uncertainty underscores the value of the FDA guidance: it signals to sponsors that some form of continuous monitoring (especially for self-learning models) is expected.

Credibility evidence should address the question of interest and COU. FDA recommends that the assessment activities, performance acceptance criteria, and documentation be commensurate with model risk and tailored to the COU; it does not prescribe a universal metric set, table format, or minimum evidence package.

Algorithmic Transparency and Interpretability

Although not explicitly labeled as a separate step, transparency is a pervasive theme. FDA expects sponsors to provide sufficient description of the model architecture, parameters, and functioning. Even for “black-box” methods like deep neural networks, some countries (and likely soon global norms) insist on explainability logs or surrogate interpretability methods (^[56]) (^[6]).

The guidance’s Appendix (and related documents) suggests disclosing model type (e.g. “random forest with 100 trees and max depth 10”), input features, and important hyperparameters. Sponsors should report how the model was tuned (grid search, Bayesian optimization, etc.) and whether pre-trained components or transfer learning were used. If proprietary or third-party models are used, the guidance acknowledges the trade secret issue (^[7]) but still requires that, at minimum, the model’s logic and feature uses be summarized in the submission (possibly under confidentiality cover).

Explainability tools (e.g. SHAP values, saliency maps) can provide evidence for transparency. FDA has encouraged (particularly for devices) that model outputs be understandable to users. In the drug context, a sponsor might include a post-hoc analysis showing which input variables most influence the prediction, or include a narrative on how the model arrived at a particular decision. The NEJM report from the 2024 workshop explicitly notes that fostering trust requires allowing end-users to “understand and effectively utilize AI outputs” (^[56]). Therefore, as part of credibility, studies that correlate model behavior to known science (e.g., a model's attributions match known pathology markers) would bolster confidence.

In practice, the detailed algorithmic documentation may often be too voluminous to submit; instead, sponsors can provide key descriptive elements in the report, and make detailed documentation available for FDA inspection. However, a summary of the model development pipeline – including feature engineering steps, algorithm choice rationales, and data preprocessing – is expected. This requirement aligns with academic guidance that “the growth of complex data-driven models requires careful quality assessment” (^[62]).

Addressing Bias and Generalizability

The FDA draft identifies dataset representativeness as a potential source of bias and reliability concerns, and it calls for credibility activities tailored to the model risk and context of use (^[63]). It does not establish a standalone fairness requirement or prescribe subgroup analyses. Where a model's stated context of use makes subgroup performance material, such analyses may be an appropriate part of a sponsor's risk-based credibility assessment.

Literature emphasizes this as well: overfitting and sample biases are common pitfalls. The NEJM workshop participants recommended extensive, representative data collection and “testing models across various demographics” (^[59]). Academic reviews of AI in healthcare note a lack of uniform guidance on bias metrics, but stress that metrics beyond overall accuracy (such as equality of odds or calibration across groups) are needed (^[8]) (^[9]). Sponsors should therefore include appropriate fairness metrics in their validation plan if applicable.

Generalizability is similarly covered by scenarios like external validation and prospective use. If a model was developed on data from one region or one manufacturing facility, regulators will want assurance it works elsewhere. Demonstrating generalizability could involve multi-center data or retraining on external datasets. A potential angle is robustness to data drift: sponsors should describe how the model will be re-assessed if the underlying data distribution changes (e.g. a new patient population or a manufacturing scale-up) (^[48]) (^[49]).

Where possible, tables or figures should be used to summarize evidence. For example, a table of model performance comparing outcomes on training vs test sets (to show absence of overfitting), or a chart of calibration curves, can be very persuasive. The FDA draft guidance itself includes illustrative tables (e.g. performance vs acceptance criteria). Sponsors are encouraged to include succinct visualizations in submissions for clarity.

Below are example tables summarizing risk assessment and innovation needs, illustrating the above concepts:

(Example: An AI recommending intensive patient monitoring (high influence) that misidentifies low-risk patients could cause severe harm (high consequence) – a high-risk case (^[5]) (^[43]). By contrast, an AI flagging some vials for human re-inspection is moderate risk because human QC mitigates consequences (^[36]).)

Table: Examples of innovations spurred by FDA’s transparency and risk requirements (^[6]).

The new AI guidance impacts various stakeholders. We examine industry and expert perspectives alongside illustrative case examples.

Many in the pharmaceutical industry view the draft guidance as pivotal. Ark Biotech characterizes it as a structured framework for assessing and addressing model risk (^[68]). The draft guidance does not itself authorize sponsors to replace experiments or manual controls; it provides nonbinding recommendations for AI-generated information or data intended to support regulatory decision-making (^[1]). For example, Ark Biotech notes FDA’s backing of simulation models “shifting the regulatory path” and enabling companies to “embrace AI with greater confidence” (^[69]) (^[70]). Their industry blog emphasizes early engagement with FDA and tailoring validation to the stated COU. Similarly, a law firm (Foley) warns clients that trade secrets will be challenged by these transparency rules, suggesting sponsors patent AI methods before disclosure (^[7]).

Surveys (e.g. Beroe/ClinicalLeader) indicate significant AI investment in pharma: while exact figures vary, one report suggests most major companies are now piloting AI in R&D (with estimates like “69% of pharma orgs invest in AI” commonly cited from industry analyses, though independent verification is limited (^[71])). Many companies have active AI pilot programs: a recent workshop revealed hundreds of industry participants, with about one-third already using AI in process development or quality control, and many planning submissions involving AI in drug manufacturing within five years (^[72]). In this light, the FDA guidance is seen as timely: stakeholders want clarity on how to present AI in new drug applications.

One recurring industry theme is risk stratification: sponsors are categorizing their AI projects as “low-, medium-, or high-risk” under FDA’s scheme, to budget appropriate resources. A DLA Piper alert summarizes this: low-risk projects (e.g. exploratory tools) require basic documentation, whereas high-risk (e.g. pivotal trial models, critical control attributes) will need detailed validation and FDA meetings (^[4]). Some companies are creating internal “AI quality units” to implement this framework. Early-industry case studies (below) illustrate this transition.

Consider the following illustrative biopharmaceutical process-development scenario, as described by Ark Biotech (^[10]): A firm is finalizing a continuous mAb manufacturing process and needs to pick the optimal perfusion rate (a parameter affecting yield and quality). Traditionally several bioreactor runs at different rates would be tested. Instead, the company built a hybrid AI model: it combines a mechanistic process simulator with machine-learning adjustment layers trained on historical bioreactor data. The model predicts process outcomes (product titer and quality attributes) across perfusion rates by simulating many scenarios (^[73]).

Applying the FDA’s 7-step framework:

• Step 1: Define the question: “What perfusion rate yields optimal product quality for Drug X?” This emphasizes a manufacturing decision tied to product quality.
• Step 2: COU: The AI model’s outputs (predicted titer, glycosylation profiles, etc.) will guide selection of the critical parameter for filing. The team specifies that this simulation complements one confirmatory run; historical runs and QC analytics will also inform the final control strategy.
• Step 3: Risk: Model influence is moderate (it suggests run at 1.75 VVD, but a validation experiment will confirm). Decision consequence is high (the perfusion rate will be included in the filing and impacts product quality). The model is thus medium-high risk.
• Step 4: Plan: The credibility plan includes gathering all historical runs (data) and results of the planned single validation run. It sets performance criteria: the model’s predicted CQA values must match the measured values within predefined acceptance intervals.
• Steps 5–6: Execute/Document: The model is run, predicts optimal perfusion 1.75, and an experimental run at 1.75 is performed, yielding product quality data. Results (prediction vs observed) are documented in the report, along with any observed noise or adjustments made.
• Step 7: Adequacy: If the model’s agreement with experiment meets the criteria (and no unanticipated biases are found), the model is deemed credible. If not (say predictions were off), the sponsor might adjust the model (additional data) or lower its influence by considering alternate evidence in setting the perfusion rate.

In Ark’s illustrative scenario, the framework shows how a sponsor could integrate AI evidence into a regulatory submission. They note that a regulatory reviewer could ask for additional supporting data or controls if needed – for instance, adding error bars to the model output to quantify uncertainty (^[10]) (^[74]). Importantly, the model was only used to inform the decision, not blindly override bench testing; this human-in-the-loop approach lowered perceived risk. Ark suggests that by following the steps, they were ready to include the AI justification in their Biological License Application.

Ark Biotech presents the following as a hypothetical example (^[75]): a continuous bioreactor is equipped with an AI-driven “digital twin” trained on process data. During a production run, a deviation occurs (the nutrient feed is delayed). The digital twin predicts that this delay (within certain bounds) will not cause out-of-specification CQAs (glycosylation, aggregation, etc.). In the hypothetical, quality assurance relies on that prediction to allow the run to continue with intensified monitoring rather than stopping the batch. The scenario assumes that subsequent CQAs remain within limits; it does not report an AstraZeneca pilot or an observed batch outcome.

Applying the framework:

• The COU is “deviation management” – using AI to decide if a batch still meets specs despite an anomaly (^[75]).
• Risk is high if the model alone were used, but here human oversight (the batch was examined by QA with the AI recommendation as input) kept it at medium risk.
• The company had planned this scenario with FDA in an early meeting, walking through the 7 steps in advance (^[74]). They had agreed on what evidence the model needed to generate (e.g. prediction accuracy vs historical deviations). They also agreed any post-call monitoring would be reported per standard deviation protocols.
• After execution, the team documented the successful run in the batch record and noted that this real-world outcome further strengthens (and updates) the model under their Continued Process Verification plan (^[76]).

This case illustrates two points: (1) Lifecycle use – the model is continuously refined with data from each run, and deviations feed back to its credibility; (2) Regulatory integration – early engagement with FDA on potential AI use in deviation management can smooth later acceptance. Ark’s blog and FDA examples both underscore that contextual controls (QA oversight, inclusion in batch records) can be used to manage risk while still benefiting from AI insights.

• Clinical Trial Design. AI is being tested for adaptive trials, patient screening, and endpoint detection. The CTTI workshop noted uses like optimizing site selection and automating imaging scoring (^[77]). For instance, an AI might predict which trial site will have better enrollment speed (risk to efficacy if wrong). Application of the credibility steps is analogous: the question (boost enrollment), COU (AI ranks sites; humans still approve), risk (wrong site = trial delay), etc.
• Real-World Evidence (RWE). AI is used to mine EHR data for safety signals or efficacy trends. Here, Step 3 flags high risk if decisions (e.g. label change) depend on the model. FDA’s guidance suggests robust external validation on separate datasets, acknowledging the earlier rule that RWE be “fit for use” in decision-making (21st Century Cures Act lineage).
• Pharmacovigilance. AI can scan large post-market databases to detect adverse events faster. This often carries less direct regulatory submission risk (it’s about surveillance), but the guidance implies even here, AI outputs should be credible (i.e. not flagging too many false positives). A “COU” could be defined as generating safety hypotheses for further investigation (lower-risk COU).

From industry and academia, there is widespread support for the guidance’s core tenets. A Future Medicine article notes the draft “emphasizes context of use and a risk-based framework” and requires sponsors to “rigorously test AI models, ensuring accuracy, reliability, and absence of bias” (^[78]) (^[79]). The NEJM AI workshop report, while predating the guidance by a few months, clearly echoes these principles and explicitly endorses a flexible risk-based approach (^[80]). In short, credible consensus is forming: safe AI in drug development needs well-defined questions, robust evidence, transparency, and ongoing oversight (^[56]) (^[81]).

The FDA’s 7-step framework is a major step in the evolving regulatory landscape for AI, but it also raises new questions and opportunities. Here we discuss how the guidance may shape future practices.

Regulatory and Industry Impact

• Shift Toward Innovation-Friendly Regulation. This guidance, along with FDA’s AI device policies, signals that regulators are open to AI-enabled approaches – provided they are properly vetted. The structured framework turns uncertainty into a plan: sponsors now have a clearer path to legitimize innovative AI methods (like in silico trials or real-time manufacturing control) under FDA review (^[69]) (^[12]). Over time, this may encourage more AI integration across the drug lifecycle, as companies can anticipate FDA’s requirements.

• Increased Documentation Burden. A downside is the higher burden on sponsors to document internal processes. Large amounts of technical detail (data dictionaries, code descriptions, validation protocols) may need to accompany applications. Foley highlights that this “poses a significant challenge for maintaining these innovations as trade secrets” (^[7]). Companies may need to choose between secrecy and compliance: e.g., filing patents on AI methods, or using FDA’s confidential information protections. There is also the practical issue of resource allocation – smaller sponsors may lack the in-house expertise to execute such thorough credibility plans, implying a potential role for AI/consultancy service providers to help.

• Global Harmonization and Guidance Convergence. Other jurisdictions are watching, and convergence is already visible. The European Medicines Agency (EMA) issued a Reflection Paper on AI in medicines (Sept 2024) emphasizing principles like transparency, data quality, and stakeholder engagement (similar to FDA). Most significantly, on January 14, 2026 the FDA and EMA jointly released the "Guiding Principles of Good AI Practice in Drug Development" — 10 high-level principles covering the entire product lifecycle, including: human-centric design, a risk-based approach, adherence to standards, clear context of use, multidisciplinary expertise, data governance and documentation, model design and development practices, risk-based performance assessment, life-cycle management, and clear essential information (^[82]) (^[83]). While the joint principles are non-binding and do not replace the FDA's draft guidance, they explicitly align with the 7-step credibility framework and foreshadow closer regulatory coordination. Companies developing AI globally will increasingly be able to plan to a shared set of expectations rather than satisfying divergent frameworks.

• Lifecycle Management and Post-Marketing Surveillance. The guidance’s model lifecycle emphasis resonates with broader FDA initiatives. For AI, this might align with existing guidelines on change management (for device software) and on pharmacovigilance (for traditional drugs). In practice, we may see sponsors integrate AI model changes into their Quality Management Systems, using mechanisms akin to Post-Approval Changes (PACMP) or Predetermined Change Control Plans (as is done for some software devices) (^[84]) (^[85]). From a practical standpoint, companies will have to plan ongoing monitoring metrics (e.g. periodic accuracy checks) and triggers for FDA notification when an AI model is updated.

• Academic and Clinical Engagement. The draft guidance may also spur academic research. Topics like “how much evidence is enough?” or “best metrics for credibility” are still open. Clinical researchers will need education on how to incorporate AI into trial designs and data analysis under this framework. In fact, CTTI and other consortia will likely produce more best-practice documents. We anticipate workshops, white papers, and perhaps FDA Q&A sessions to clarify requirements (e.g. How to choose performance limits? How to validate generative models?). The ultimate test will be how FDA reviewers apply this draft: sponsors should carefully study approval letters and review templates once some AI-inclusive submissions are public.

Challenges and Open Questions

• Regulatory Submissions Practices. The guidance leaves timing and form of submissions somewhat flexible. Will sponsors be expected to submit the credibility report with every application, or only upon request? The draft suggests discussing “whether, when, and where” with FDA (^[86]), which implies continued uncertainty. This ambiguity can be tricky – companies must decide how much to proactively share. Some may choose to proactively include the plan in an IND package, whereas others might wait for a Biologics License application. The decision may hinge on model risk and novelty.

• Measuring Uncertainty and Explainability. Deep learning models and large language models (LLMs) are increasingly used in life sciences. The FDA brief mentions Bayesian models favorably for uncertainty quantification (^[45]). It remains an open question how regulators will view LLM-based tools (e.g. for line listings or literature review). Will these fall under the same framework, or require a variant? The principles (COU, risk) still apply, but specific metrics for generative models (like hallucination error rates) are still being defined.

• Integration into Quality Systems. The guidance hints that life-cycle maintenance should be part of a firm’s pharmaceutical quality system (^[84]). In practice, this means CMOs, manufacturers, and sponsors need to establish standard operating procedures for AI. Questions arise: Should AI governance be part of current Computer System Validation (CSV) practices? Who “owns” AI errors? Historically, efficacy and safety liability rests with the sponsor, but when an AI is co-developed by a software vendor, new legal and operational models may emerge.

• Ethical and Social Considerations. The guidance is primarily technical and science-focused, but it implicitly invokes ethical concerns (bias, transparency, patient welfare). We expect future FDA and HHS discussions on governance frameworks that align with AI ethics principles (e.g. fairness, accountability). Already, FDA’s mention of “responsible and ethical use” in the press release (^[87]) hints at broader values. Real-world case: if an AI exclusion model wrongly excludes a minority patient group from beneficial therapies, the credibility framework should capture this risk even if outcomes look “accurate” on average. Sponsors must ensure diverse stakeholder input likely in such scenarios.

Future Directions

Looking ahead, several developments may build on this guidance:

• International Collaboration: The FDA indicates plans to “engage globally to explore opportunities for harmonizing terminology and basic principles” (^[88]). We may see joint FDA-EMA workshops or even ICH discussions on AI model validation guidelines. Global pharmaceuticals companies will greatly welcome any convergence.

• Tool Standardization: As the framework sinks in, tool vendors and CROs may develop standardized credibility toolkits – software to track steps, automate parts of documentation, and even guide metric calculations. Analogous to how bioinformatics has QC pipelines, we may see ML operations (MLOps) adapted to pharma regulation.

• Case Law and Policy: If high-profile cases arise (e.g. a mishap blamed on an AI decision), it could spur tighter rules. Conversely, successful real-world uses will build trust. The draft guidance is non-binding (“current thinking”) – stakeholders will watch how it evolves after public comment and see what becomes final.

• Next-Generation AI: The guidance addresses traditional ML today. By 2030, new AI paradigms (e.g. quantum ML, autonomous labs, AI-curated data networks) may challenge it. FDA will likely iterate on policy. In fact, FDA has already solicited input on “real-world performance of AI medical devices” (^[89]), a hint they want to keep updating their approach.

To ground the 7-step framework in quantitative terms, we review some key performance considerations and studies:

• Performance Metrics: A recent scoping review found that common metrics in clinical AI include Area Under the ROC Curve (AUROC), sensitivity, specificity, and predictive values (^[8]). These traditional measures are a good starting point, but they may not suffice for regulatory credibility. For example, AUROC summarizes separation across all thresholds, which may hide performance issues at clinically relevant thresholds. Therefore, sponsors should pick metrics that directly tie to clinical impact (e.g. false-positive rate at the operational threshold). In line with standards for predictive models (^[90]), the FDA framework’s credibility plan might also require specifying sample size calculations for validation (e.g. ensuring at least N events for power).

• Monitoring Over Time: The ongoing performance of AI models is critical. A 2024 review on monitoring clinical AI noted a dearth of rigorous methods and guidance (^[61]), highlighting an evidence gap that the FDA’s emphasis on life-cycle monitoring aims to fill. It found a jump in publications on AI monitoring by 2023, signaling growing interest. Reported monitoring strategies include re-calibration of risk scores, control charts of error rates, and periodic re-training schedules. ADAs (algorithmic drift alarms) might be part of the plan.

• Uncertainty Quantification: Bayesian approaches and confidence intervals are gaining attention. For example, if a predicted probability of success is 0.85±0.05, the sponsor should interpret the ±0.05 as part of credibility evidence. The guidance encourages characterizing uncertainty “especially for high-risk AI” (^[91]). This resonates with proposals in the literature to communicate uncertainty in risk-model outputs, for example through credible intervals for treatment benefit.

• Bias and Fairness Evidence: While not explicitly enumerated in the steps, fairness must be demonstrated indirectly by showing consistent performance. If the model is to be used broadly, sponsors should include subgroup analyses (e.g. by age, sex, comorbidity) in the report, and declare any observed performance gaps. This aligns with recommendations from fairness audits in health AI (^[92]). No publicly available statistics on bias in specific FDA submissions exist, but systematic bias is a known risk (e.g. a 2023 eBioMedicine commentary noted that fairness metrics are still immature in healthcare contexts (^[92])).

• Data Science Best Practices: Established practices (train/test splits, cross-validation, feature selection, hyperparameter tuning, ensemble methods) underpin rigorous AI. The guidance implies these through terms like “model tuning” and “validation,” but does not forbid novel methods. For example, ensemble or federated learning approaches, often touted in pharma, can be used – but FDA would expect the same credibility steps applied (e.g. if federated learning is used, sponsors would need to explain data sources and how federated training was validated).

In sum, quantitative data analysis can provide credibility evidence for steps 5–6. The draft guidance does not establish TRIPOD reporting or cross-validation as regulatory requirements. Voluntary reporting frameworks, such as TRIPOD when applicable to a prediction-model study, and techniques such as cross-validation can be context-dependent ways to document model evaluation. FDA recommends choosing evaluation methods that are commensurate with model risk and tailored to the COU.

The following considerations supplement the preceding implications, challenges, and future-directions analysis.

• Regulatory Strategy and IP. The draft guidance is nonbinding and recommends methodological transparency appropriate to establishing credibility; it does not prescribe a patent-versus-trade-secret strategy (^[63]). Sponsors may wish to evaluate regulatory disclosure and IP considerations case by case with qualified counsel. Under FDA disclosure rules, submitted information that meets the definitions of trade secret or confidential commercial or financial information is not available for public disclosure, subject to applicable law (^[93]).

• Quality Management Systems (QMS). AI credibility will need to be integrated into existing QMS and Quality by Design approaches. For drugs, the ICH Q8-Q10 suite currently covers risk mgmt of processes, but not specifically AI models. We may see new guidance (or updates to existing quality guidelines) that explicitly address algorithmic changes. Companies have begun to include AI governance in their CSV/QMS infrastructure: e.g. defining roles like “AI steward”, specifying documentation templates, and including AI topics in audits. Going forward, inspection criteria for AI use will evolve.

• Harmonization with Medical Device AI. Many future therapies are drug-device combinations or software-driven devices. FDA’s January 2021 Artificial Intelligence and Machine Learning Software as a Medical Device Action Plan was an action plan, not a guidance. FDA later issued final guidance, Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions (August 2025; FDA-2022-D-2628), for AI-enabled devices. While that guidance is device-focused, principles overlap: evaluating safety and effectiveness and planning and assessing future modifications. Pharmaceutical AI developers should be aware of this parallel. There could be joint consultations if a drug’s AI system has a device component. Harmonizing credibility frameworks across product types will be an interesting policy issue.

• Impact on Innovation Ecosystem. Paradoxically, while the guidance imposes controls, experts see it as pro-innovation. By delineating a clear pathway, smaller biotech/tech startups might feel more confident pitching AI solutions for regulated drug programs, knowing what evidence to collect. FDA's January 2025 draft guidance provides a risk-based credibility assessment framework for evaluating an AI model's credibility for a particular context of use (^[1]).

• Patient Safety and Healthcare Delivery. Ultimately, the credibility framework is about patient safety. All the risk and evidence work is in service of confidence that an AI decision will not harm patients or degrade product quality. If successfully implemented, it could lead to more efficient clinical trials (fewer patients exposed unnecessarily), improved manufacturing robustness (fewer batch failures), and perhaps faster drug approvals due to predictive modeling. In the broader health ecosystem, this framework may serve as a model for how to regulate AI in other contexts (e.g. diagnostic AI or even consumer health AI) with a risk-based, context-specific approach.

• Evolution of Guidance. The initial 90-day comment period for the draft ended on April 7, 2025, but FDA states that comments on any guidance may be submitted at any time. The FDA continues to list this document as Draft Level 1 Guidance, "Not for implementation," containing non-binding recommendations (^[1]). Stakeholders have highlighted ambiguities in how to apply the steps to novel AI types — particularly generative AI and large language models, which were barely in scope when the draft was written in late 2024. Open questions include what constitutes a sufficient model-risk assessment, how to handle ensemble models with evolving architectures, how to manage "AI-as-a-service" from external vendors, and whether generative/LLM-based tools require a variant framework. A January 2026 critical review in the Journal of Chemistry (^[94]) identified the draft's limited treatment of these novel model classes as a gap.

• Ethics and Trust. Although the guidance is technical, its risk-based framework is intended to help sponsors establish and evaluate credibility evidence for AI model outputs in a particular context of use (^[63]). The draft does not expressly require a demonstration of fairness. Broader ethical oversight and patient-facing explanations may require considerations beyond this guidance.

The FDA’s draft AI guidance for drug and biologic development describes a structured, risk-based 7-step credibility framework (^[3]). The non-binding framework may help sponsors plan, gather, organize, and document credibility evidence for AI outputs used to support regulatory decision-making. Sponsors should consider defining the decision problem, delineating the AI’s context of use, assessing model risk, and gathering evidence through planned validation and documentation (^[11]) (^[5]). Applicable statutes, regulations, and product-specific FDA requirements remain controlling.

Our analysis shows that this framework is grounded in well-established principles of model validation and risk management. For example, it echoes quality guidelines by emphasizing adequate sample sizes and test independence (^[58]), and it aligns with calls from workshops to make AI outputs interpretable and continuously monitored (^[56]) (^[61]). In practice, its application can unlock new efficiencies: case studies in bioprocess development and quality control demonstrate how high-stakes decisions (e.g. setting a bioreactor perfusion rate, managing a batch deviation) can be informed by AI as part of a broader evidence ecosystem (^[10]) (^[75]).

However, implementation will require effort. Industry must adapt systems for intellectual property, maintain detailed data and metadata records, and possibly re-engineer workflows to integrate this framework. FDA emphasizes early engagement, which will be key; companies should not treat the framework as purely a post-hoc paper exercise, but as a guide to building credibility from day one. The guidance also sparks innovation: it effectively invites technologists to develop explainability tools, bias-correction systems, and AI QA platforms that satisfy regulatory needs (^[6]).

Going forward, we expect this guidance to evolve. The FDA will refine the approach through its public comment process and future experiences, and international counterparts will likely echo its core ideas. For stakeholders across pharma, biotech, and AI fields, the take-home message is clear: AI is welcome in drug development – but only with a solid foundation of trustworthiness. By following the 7-step framework, sponsors can demonstrate to regulators (and to the public) that their AI models are not inscrutable or unchecked, but rigorously vetted tools contributing to safe, effective medical products (^[14]) (^[13]).

References: The analysis above integrates the FDA’s draft guidance and reporting on it (^[2]) (^[5]), expert commentary from industry sources (^[28]) (^[10]), and academic studies on AI model validation (^[16]) (^[8]), among others, all cited in the text.